^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JCAR018

i
Other names: JCAR018, anti-CD22 chimeric antigen receptor T-cells, T-cell chimeric antigen receptor cellular therapy targeting CD-22, CD22-CAR, JCAR-018, JCAR 018, anti-CD22-human scFv CAR T cell therapy
Associations
Company:
BMS, National Cancer Institute
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
Associations